CS-2009

N/A

Report date: 2026/02/27 20:01:47

Base Information

Drug NameCS-2009
Drug Alias NameCS-2009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 blockersVascular endothelial growth factor A inhibitorsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsProgrammed cell death protein 1Vascular endothelial growth factor ACytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCstone Pharmaceuticals
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenshi Pharmaceuticals (Shanghai) Co LtdCstone PharmaceuticalsCstone Pharmaceuticals (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A